Rajiv Ranjan, MD
Cardiovascular Disease · Norfolk, NENPI 1679520225
Payments from drug & device makers
Across 48 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$235
- Medtronic$140
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$128
- Pfizer$76
- E.r. Squibb & Sons, L.L.C.$55
- Penumbra, Inc.$44
- plus $258 from 14 others
What the payments were for
- Food & beverage$936100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $235 |
| Medtronic(2 entities) | 8 | $140 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $128 |
| Pfizer | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Penumbra, Inc. | 1 | $44 |
| Johnson & Johnson | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Chiesi USA, Inc. | 2 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Amgen | 1 | $17 |
| Terumo Medical Corporation | 1 | $15 |
| Abiomed | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$936 in reported general payments places this provider in the 25th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 12 | $308 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Norfolk
- Muhammad ImranNorfolk$4K
- Eric RomeNorfolk$1K
- Ronald ZoltyOmaha$6.3M
- Robert PercellLincoln$1.3M
- Steven KruegerLincoln$840K
- Chad TraversLincoln$594K
- Jeffrey CarstensOmaha$299K
- Joseph ThibodeauOmaha$251K
- Keith MillerLincoln$204K
- John SteuterLincoln$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.